Literature DB >> 10473885

Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy.

A W Saleh1, H F Hillen, A J Duits.   

Abstract

It has been shown that the clinical course of sickle cell (SS) patients can be ameliorated by administration of hydroxyurea (HU). Induction of hemoglobin F (HbF) is thought to be the mechanism responsible for clinical improvement in some patients. However, HU has a variable effect on HbF production and there exists no good correlation between the extent of HbF increase and clinical response. On the other hand, the degree of adherence of SS to vascular endothelium and neutrophil counts correlate well with clinical severity. Being a cytotoxic drug, used in myeloproliferative diseases, HU may alter proliferation among various cell lines. Moreover, HU has been reported to reduce red blood cell (RBC) adhesion receptor expression in young SS individuals and induces changes in endothelial cells in vitro. It should be conceived that in addition to its effects on HbF production, HU may change the clinical symptoms of SS patients by affecting the degree of adherence of different blood cells, by influencing the activity of endothelium as well as the activity of white blood cells (WBC) and platelets. To analyze whether several of the determinants of adhesion are modulated by HU treatment we studied the levels of endothelial activity (soluble vascular adhesion molecule-1, (sVCAM-1), interleukin-8 (IL-8), fibronectin, neutrophil activity (sL-selectin, sIL-6 receptor-alpha, myeloperoxidase) and platelet activity (von Willebrand factor) in relation to clinical symptoms, hematological data and HbF levels in 8 SS patients before and during 5 months of HU therapy. Steady state sVCAM-1 levels are increased compared to normal controls and a significant decrease is noted during HU treatment, suggesting a decrease in the interactions between RBC and vascular endothelium. The IL-8 levels are comparable to those in normal controls and remain unaffected by HU therapy. Intercurrent infection and crises reveal striking increases in IL-8 which are accompanied by leukocytosis, but otherwise the IL-8 levels do not correlate with hematological data. HU has no demonstrable effect on fibronectin or soluble neutrophil adhesion molecules, but the levels of myeloperoxidase decrease significantly while WBC counts do not, implying a reduction in neutrophil activity which may help attenuate the propagation phase of a vasoocclusive crisis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10473885     DOI: 10.1159/000040964

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  24 in total

1.  Aggregation of mononuclear and red blood cells through an {alpha}4{beta}1-Lu/basal cell adhesion molecule interaction in sickle cell disease.

Authors:  Vicky Chaar; Julien Picot; Olivier Renaud; Pablo Bartolucci; Ruben Nzouakou; Dora Bachir; Frédéric Galactéros; Yves Colin; Caroline Le Van Kim; Wassim El Nemer
Journal:  Haematologica       Date:  2010-06-18       Impact factor: 9.941

Review 2.  The paradox of the neutrophil's role in tissue injury.

Authors:  George B Segel; Marc W Halterman; Marshall A Lichtman
Journal:  J Leukoc Biol       Date:  2010-11-19       Impact factor: 4.962

Review 3.  Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology.

Authors:  Dachuan Zhang; Chunliang Xu; Deepa Manwani; Paul S Frenette
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

4.  Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality.

Authors:  Gregory J Kato; Sabrina Martyr; William C Blackwelder; James S Nichols; Wynona A Coles; Lori A Hunter; Marie-Luise Brennan; Stanley L Hazen; Mark T Gladwin
Journal:  Br J Haematol       Date:  2005-09       Impact factor: 6.998

Review 5.  Sickle cell disease: old discoveries, new concepts, and future promise.

Authors:  Paul S Frenette; George F Atweh
Journal:  J Clin Invest       Date:  2007-04       Impact factor: 14.808

6.  Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.

Authors:  Gregory J Kato; Vicki McGowan; Roberto F Machado; Jane A Little; James Taylor; Claudia R Morris; James S Nichols; Xunde Wang; Mirjana Poljakovic; Sidney M Morris; Mark T Gladwin
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

7.  Neutrophils and leucocyte adhesion molecules in sickle cell retinopathy.

Authors:  M Kunz Mathews; D S McLeod; C Merges; J Cao; G A Lutty
Journal:  Br J Ophthalmol       Date:  2002-06       Impact factor: 4.638

Review 8.  Pediatric sickle cell disease: past successes and future challenges.

Authors:  Emily Riehm Meier; Angeli Rampersad
Journal:  Pediatr Res       Date:  2016-10-05       Impact factor: 3.756

9.  Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial.

Authors:  Carolyn Hoppe; Eufemia Jacob; Lori Styles; Frans Kuypers; Sandra Larkin; Elliott Vichinsky
Journal:  Br J Haematol       Date:  2017-03-28       Impact factor: 6.998

10.  Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?

Authors:  Courtney D Fitzhugh; Matthew M Hsieh; Charles D Bolan; Carla Saenz; John F Tisdale
Journal:  Cytotherapy       Date:  2009       Impact factor: 5.414

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.